Value
7.9/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 7.9 |
| Fwd P/E | 5.5 |
| Analyst target | 9.0 |
- ▸Forward P/E: 23.2x
- ▸Attractively valued
HCM · Why this verdict
Why HUTCHMED (China) (HCM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue declined 16% year-over-year, and with no evidence of an impending inflection, the growth dimension scores at the weakest possible level — a direct contradiction to any forward thesis that this is a growth asset, regardless of headline margin or return metrics. Growth breakdown | Revenue growth turns positive (above 0%) for 2 consecutive reporting periods, confirming the contraction has bottomed and a recovery is underway. | →Stable |
| CounterIn specialty pharmaceutical development, revenue can be lumpy around drug approvals, licensing events, or partnerships; a 16% decline may reflect a natural trough between pipeline catalysts rather than permanent impairment to the top line. | ||
Despite reported margins of 83% and a return on equity of 45%, the Piotroski F-Score stands at just 1 out of 9 — the weakest possible financial health signal — and free cash flow is negative relative to net income, indicating that the attractive headline figures mask severe underlying financial strain. Quality breakdown | Piotroski F-Score rises above 5 out of 9 for 2 consecutive annual periods, confirming the financial health picture is genuinely improving. | →Stable |
| CounterA single reporting period with weak working capital or cash flow dynamics can depress the Piotroski score temporarily; if the underlying business drivers remain sound, the score could recover to the midrange within one or two quarters as the balance sheet normalizes. | ||
A confirmed death cross, momentum well below the minimum passing threshold, falling on-balance volume, and a 200-day moving average sloping downward at 4.9% per month collectively constitute a hard technical block — price has no confirmed floor and every technical signal points to continued selling pressure. Engine gate (failed) | The death cross reverses (short-term moving average crosses back above the long-term average) and is maintained for 4 consecutive weeks, confirming the downtrend has ended. | →Stable |
| CounterWith analyst consensus implying roughly 83% upside to the price target, a single pipeline catalyst or positive regulatory event could produce a sharp re-rating that breaks the technical structure to the upside before the moving averages have time to recover. | ||
The trailing P/E is near 4x — implying very high recent earnings — while the forward P/E has expanded to roughly 22x, a more than five-fold expansion that signals the market expects a dramatic decline in near-term earnings; this pattern is consistent with a cyclical earnings peak that makes current reported profitability a potentially misleading anchor for valuation. Bear case | Forward P/E compresses back below 10x from the current 22x as earnings guidance stabilizes or recovers, removing the cyclical-peak concern. | →Stable |
| CounterIf the large upside to the analyst consensus price target materializes through pipeline progress or commercial ramp, the forward P/E expansion may simply reflect a transitory earnings trough rather than structural impairment, and the stock could re-rate sharply as those earnings recover. | ||
Revenue declined 16% year-over-year, and with no evidence of an impending inflection, the growth dimension scores at the weakest possible level — a direct contradiction to any forward thesis that this is a growth asset, regardless of headline margin or return metrics.
→StableGrowth breakdown
- Expectation
- Revenue growth turns positive (above 0%) for 2 consecutive reporting periods, confirming the contraction has bottomed and a recovery is underway.
CounterIn specialty pharmaceutical development, revenue can be lumpy around drug approvals, licensing events, or partnerships; a 16% decline may reflect a natural trough between pipeline catalysts rather than permanent impairment to the top line.
Despite reported margins of 83% and a return on equity of 45%, the Piotroski F-Score stands at just 1 out of 9 — the weakest possible financial health signal — and free cash flow is negative relative to net income, indicating that the attractive headline figures mask severe underlying financial strain.
→StableQuality breakdown
- Expectation
- Piotroski F-Score rises above 5 out of 9 for 2 consecutive annual periods, confirming the financial health picture is genuinely improving.
CounterA single reporting period with weak working capital or cash flow dynamics can depress the Piotroski score temporarily; if the underlying business drivers remain sound, the score could recover to the midrange within one or two quarters as the balance sheet normalizes.
A confirmed death cross, momentum well below the minimum passing threshold, falling on-balance volume, and a 200-day moving average sloping downward at 4.9% per month collectively constitute a hard technical block — price has no confirmed floor and every technical signal points to continued selling pressure.
→StableEngine gate (failed)
- Expectation
- The death cross reverses (short-term moving average crosses back above the long-term average) and is maintained for 4 consecutive weeks, confirming the downtrend has ended.
CounterWith analyst consensus implying roughly 83% upside to the price target, a single pipeline catalyst or positive regulatory event could produce a sharp re-rating that breaks the technical structure to the upside before the moving averages have time to recover.
The trailing P/E is near 4x — implying very high recent earnings — while the forward P/E has expanded to roughly 22x, a more than five-fold expansion that signals the market expects a dramatic decline in near-term earnings; this pattern is consistent with a cyclical earnings peak that makes current reported profitability a potentially misleading anchor for valuation.
→StableBear case
- Expectation
- Forward P/E compresses back below 10x from the current 22x as earnings guidance stabilizes or recovers, removing the cyclical-peak concern.
CounterIf the large upside to the analyst consensus price target materializes through pipeline progress or commercial ramp, the forward P/E expansion may simply reflect a transitory earnings trough rather than structural impairment, and the stock could re-rate sharply as those earnings recover.
TrendMatrix Research · core thesis
Engine thesis — one sentence
A specialty pharmaceutical developer with reported margins of 83% and a return on equity of 45% is undermined by 16% revenue contraction, a Piotroski F-Score of just 1 out of 9, a hard-blocked technical downtrend, and a forward P/E that implies a near-complete collapse in near-term earnings — making this a situation where patience is warranted until the fundamental and technical picture improves materially, despite a large stated upside to analyst consensus.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 10.0 |
| Current ratio | 8.0 |
| FCF quality | 0.0 |
| Moat | 4.2 |
| Piotroski F | 1.1 |
- ▸Excellent ROE: 45%
- ▸Strong margins: 83%
- ▸Earnings quality RED FLAG: -12% FCF/NI
- ▸No competitive moat
Growth
0.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
| EPS growth | 0.0 |
- ▸Declining revenue: -16%
Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.8 |
| MACD | 9.7 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 8.9 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -5.2%/30d — confirmed downtrend
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 9.0 |
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.80 (n=1)
- ▸Analyst upside: 100%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.6 |
| quality rank | 9.6 |
| growth rank | 0.7 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.1 |
| 52w position | 1.7 |
| gap | 3.0 |
- ▸Extreme gap up (5.0%) - may pull back
Risk (lower is worse)
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.9 |
| days to cover | 7.5 |
| volatility | 4.3 |
| beta | 10.0 |
| debt equity | 0.0 |
Catalyst
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.3>=5.5
- ASYMMETRY:5.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=7.3>=5.0 recovering
Reward-to-Risk
5.05
Upside
+73.7%
Downside
14.6%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 62
EdgeCatalyst-Driven — Earnings in 27d with 3/4 beat streak
SuitabilitySpeculative — Drawdown -41% (>40% off 52w high)
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.9 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 7.9, Sentiment at 7.8, and Momentum at 7.3; the weakest are Growth at 0.0, Technical at 1.4, and Quality at 3.7. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 5.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue Contracting 16pct
Trip ifRevenue growth turns positive above 0% for 2 consecutive reporting periods, confirming the contraction has reversed.
- P2Quality Below Floor Piotroski 1 Of 9
Trip ifPiotroski F-Score rises above 5 out of 9 for 2 consecutive annual reporting periods, confirming financial health recovery.
- P3Confirmed Downtrend Hard Technical Block
Trip ifShort-term moving average crosses above the long-term moving average (death cross reversal) and holds for 4 consecutive weeks.
- P4Cyclical Trap Forward Pe Expansion
Trip ifForward P/E compresses below 10x from the current 22x as earnings estimates stabilize or improve.